Kaya Holdings, Inc. announced that it has launched Fifth Dimension Therapeutics™, which will seek to provide psychedelic "mind care" treatments to veterans suffering from PTSD, addicts seeking to break addiction, individuals with eating disorders, and others with a wide array of treatment resistant mental health disorders. The Company announced that one of its senior employees, Bryan Arnold, has been enrolled in one of the first training courses to qualify for an Oregon Psilocybin Facilitator License, permitting him to oversee the cultivation of psilocybin mushrooms and related products as well as operate up to five state licensed facilitation clinics where psilocybin treatments will be administered. Bryan is expected to complete his training and apply for licensure in April.

Additionally, the Company is proud to welcome attorney Glenn E.J. Murphy to the FDT Board of Director. Glenn will assist FDT with introductions to pharmaceutic companies seeking data and access to psychedelic patients, as well as advising on the development of intellectual property, structure of potential joint ventures, funding opportunities, acquisitions, and other related endeavors. Mental health disorders account for several of the top causes of disability in the United States.

A 2021 Harvard University study forecasted the annual medical cost of mental health conditions to reach $6 trillion by 2030. It is estimated by the National Institute of Mental Health Disorders that 26% of Americans over 18 years of age suffer from a diagnosable form of depression (major or clinical depression, manic or bipolar depression), and an additional 40 million American adults suffer from an anxiety disorder. Depressive illnesses tend to co-occur with substance abuse and anxiety disorders.

In 2021, Data Bridge Market Research estimated the current U.S. psychedelics market value to be $2.8 billion, with a forecasted 2029 market expected to reach $8.9 billion. The Science The growing evidence suggests that psychedelics act on the brain's default network, or those regions of the brain that remain active when brain is not engaged in active tasks. Psilocybin increases activity in certain neurons that respond to the neurotransmitter serotonin, which has wide- ranging functions in the human brain.

Psychedelics seem to suppress the default network, relaxing the separation of senses, memories, thoughts, and emotions, and enabling each to influence each other more easily. This ability to break down of the brain's "framework" has led to a focus on psychedelics as a groundbreaking opportunity to address a wide range of mental health disorders. Glenn Murphy's Biography Glenn has twenty-five years of private and corporate practice, including ten years in-house with the Henkel Group and more than fifteen years in private practice, Glenn's experience has touched on most every aspect of intellectual property practice.

Glenn's current practice primarily focuses on building and managing domestic and international utility and design patent portfolios and opining on the validity and infringement of U.S. patents. In addition to drafting and prosecuting patent applications filed in the U.S. and foreign patent offices, Glenn has briefed and argued before the U.S. Patent Office Board of Appeals, assisted with the preparation and argument of appeals before the U.S. Court of Appeals for the Federal Circuit, and assisted with the conduct of bench and jury trials in the U.S. District Courts and the U.S. International Trade Commission. He has provided due diligence and advice in acquisitions, divestments, licenses, and other transactions involving intellectual property rights.

He has particular experience in building and managing domestic utility and design patent portfolios for non-U.S. clients. After receiving his B.S. in chemical engineering in 1984 from the Pennsylvania State University, Mr. Murphy worked as an engineer for the Cochrane Division of Crane Company, designing and delivering large-scale water treatment systems for industry. In 1990 he received his J.D. with honors from the University of Pittsburgh School of Law, where he served as an editor of the school's Journal of Law and Commerce and received the Faculty Award for Excellence in Legal Scholarship.